RecruitingNCT05438836
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Sponsor
Herlev Hospital
Enrollment
205 participants
Start Date
Jan 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Biopsy-verified anal cancer
- Eligible for curative intended radiotherapy
- Written and oral consent
Exclusion Criteria1
- Other malignant disease within the past 5 years (excluding basal cell carcinoma)
Interventions
RADIATIONonline adaptive radiotherapy
Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05438836
Related Trials
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT0492902814 locations
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT072171718 locations
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT064930194 locations
Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy
NCT040944541 location
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
NCT060507074 locations